Your browser doesn't support javascript.
loading
Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher.
Jabbour, Elias J; Short, Nicholas J; Jain, Nitin; Jammal, Nadya; Jorgensen, Jeffrey; Wang, Sa; Wang, Xuemei; Ohanian, Maro; Alvarado, Yesid; Kadia, Tapan; Sasaki, Koji; Garris, Rebecca; Garcia-Manero, Guillermo; Ravandi, Farhad; Kantarjian, Hagop M.
Afiliação
  • Jabbour EJ; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Jammal N; Department of Pharmacy, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Jorgensen J; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang S; Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang X; Department of Biostatisitcs, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Ohanian M; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Alvarado Y; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia T; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Sasaki K; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Garris R; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia-Manero G; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian HM; Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 97(9): 1135-1141, 2022 09.
Article em En | MEDLINE | ID: mdl-35713551
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Linfoma de Burkitt / Anticorpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Linfoma de Burkitt / Anticorpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article